POHCA Resuscitation: Evaluation of IM Epinephrine

IM epinephrine may provide a more efficient means of administering the initial epinephrine dose (versus IV/IO administration) to a child experiencing pediatric out of hospital cardiac arrest (POHCA) with no greater risk of harm. In so doing, this may improve the short- and long-term outcomes of these patients. There is an abundance of literature detailing the risk/benefit profile of IM epinephrine use in anaphylaxis; however, there is no human data on this topic as it relates to cardiac arrest. Important knowledge gaps include whether the use of IM epinephrine via autoinjector and/or pre-filled syringe leads to faster administration of the initial doses of epinephrine without delaying time to definitive epinephrine (via IV/IO) and the impact on time to initial and sustained return of spontaneous circulation (ROSC). This trial will be the first to examine the role of IM epinephrine via autoinjector/pre-filled syringe in POHCA.

• Return of spontaneous circulation [Срок оценки: At time of event]
• Time to sustained ROSC [Срок оценки: At time of event]
• Survival [Срок оценки: From time of event to ED admission]
• Survival - comparison between both arms [Срок оценки: From time of event to hospital admission]
• PCCU/Hospital length of stay [Срок оценки: From time of hospital/PCCU admission to discharge, up to 1 year]
• Survival to hospital discharge [Срок оценки: Dependent on course of hospital stay, up to 1 year]
• Post POHCA survival [Срок оценки: Dependent on survival at 6 and 12 month period post POHCA event]
• Neurological status [Срок оценки: From time of discharge and 6 and 12 months post POHCA event]
• Life Impact and Pediatric Quality of Life assessments [Срок оценки: 6 and 12 months post POHCA event]
• Life Impact and Pediatric Quality of Life assessments [Срок оценки: 6 and 12 months post POHCA event]